Immune Response of Intradermal Hepatitis B Vaccination at Lower Dose versus Intramuscular Vaccination at Double Standard Dose in Predialytic Chronic Renal Failure Patients

Journal of the Medical Association of Thailand

Volumn 86, Issue 12, 2003, Pages 1122-1127

  Somboonsilp, Wanida ^a   Tungsanga, Kriang ^b   Eiam Ong, Somchai ^b   Tirawatanapong, Thaweesak ^b  

^a Ministry of Public Health   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Hepatitis B Vaccination; Intradermal Route; Intramuscular Route

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MALE; SEROCONVERSION;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 1542299111     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Haag-Weber M, Horl WH. Uremia and infection: Mechanism of impaired cellular host defence. Nephron 1993; 63: 125-31.
2. Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int 1993; 43 (Suppl 41): S135-42.
3. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiveing hemodialysis. N Engl J Med 1984; 23: 496-501.
4. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-20.
5. Benhamau E, Courouce AM, Jungers P, et al. Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143-7.
6. Kohler H, Arnold W, Renschin G, Dormeyer H, Zum Bushendelde KM. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124-8.
7. de Graeff PA, Dankert J, de Zeenw D, Gips CH, van der Hem GK. Immune response to two different hepatitis B vaccines in haemodialysis patients: A 2-year follow-up. Nephron 1985; 40: 155-60.
8. Joe PB, Maria S, Mohammed I, et al. Comparative trial of low dose introdermal, recombinant and plasma-derived hepatitis B vaccines. J Infect Dis 1990; 162: 789-93.
9. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramusscular administration of hepatitis B vaccine: Side effects and antibody response. Scan J Infect Dis 1987; 19: 617-21.
10. Lefebure AF, Verpooten GA, Couttenye MM, DeBroe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993; 11: 397.
11. Van Geelen JA, Schaim SW, de Visser EM, Heijtink RA. Immune response to hepatitis B vaccine in hemodialysis patients. Nephron 1987; 45: 216-8.
12. Buti M, Validomiu L, Jardi R, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12: 144-7.
13. Andre FC, MC Dougall J, Goldstein MB. Randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-82.
14. Guan R, Tay HH, Choong HL, Yap I, Woo KT. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: The immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Ann Acad Med Singapore 1990; 19: 793-7.
15. Drachman R, Isacsohn M, Rndensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant 1989; 4: 372-4.
16. Marangi AL, Giordano R, Montanaro A, et al. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992; 61: 331-2.
17. Dentico P, Volpe A, Buongiorno R, et al. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients. Nephron 1992; 61: 324-5.
18. Bergia R, Pellerey M, Berto I, et al. Hepatitis B vaccination in uremic patients: Comparison between recombinant and plasma-derived vaccine. Nephron 1992; 61: 328.
19. Favero MS, Alter MJ. The reemergence of hepatitis B virus infection in hemodialysis centers. Semin Dial 1996; 9: 373-4.
20. Prost T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-5.
21. Nagafuchi S, Kashiwagi S, Inoue T, Imagama S. Development of skin reaction to hepatitis B vaccine in man. Micro Biol Immunol 1984; 28: 257-9.
22. Nagafuchi S, Kashiwagi S, Hayashi S. Delayed type hypersensitivity (DTH) skin reaction to hepatitis B surface antigen (HBsAg) in patients with type B acute and chronic hepaitits. Clin Exp Immunol 1985; 61: 569-76.
23. Payton CD, Scarisbrick DA, Sikotra S, Flower AJE. Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidermiol Infect 1993; 110: 177-80.
24. Seaworth B, Drucker J, James S, Robert D, Cladd S, John H. Hepatitis B vaccines in patients with chronic renal failure bofore dialysis. J Infect Dis 1988; 157: 332-7.
25. Rangel MC, Coronado VG, Euler GL, Strikas RA, Vaccine recommendations for patients on chronic dialysis. Sem Dial 2000; 13: 101-7.
26. Vazquez G, Mendoza-Guevara L, Alvarez T, et al. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration. Adv Perit Dial 1997; 13: 291-6.
27. Bommer J, Grussendof M, Jilg W, et al. vaccination against hepatitis B in patients with renal insufficiency. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 300-5.
28. Mettang T, Schenk U, Thomas S, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. Nephron 1996; 72: 192-6.
29. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: A cost reduction strategy. JAMA 1985; 254: 3203-6.
30. Zelickson A. The Langerhans cell. J Invest Dermatol 1965; 44: 201-13.
31. Braathen L, Thorsby E. Studies on human epidermal Langerhans cells: I Allo-activating and antigen-presenting capacity. Scand J Immunol 1980; 11: 401-8.
32. Charanasri U, Kingnate D, Meesomboon V, Samuthananon P, Chaeychomsri W. Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. J Med Assoc Thai 1992; 75: 639-42.
33. Ubol S, Phanuphak P. An effective economical intradermal regimen of human diploid cell rabies vaccination for post-exposure treatment. Clin Exp Immunol 1986; 63: 49-7.
34. WarTell MJ, Nicholson KG, Warrel DA. Economical multiple site intradermal immunization with human diploid cell strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 1: 1959-62.
35. Rault R, Freed B, Nespor S, Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO 1995; 41: M17-9.
36. Ono K, Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47-51.